← Back to Screener
Apyx Medical Corporation Common Stock (APYX)
Price$3.94
Favorite Metrics
Price vs S&P 500 (26W)25.26%
Price vs S&P 500 (4W)4.87%
Market Capitalization$166.48M
All Metrics
Book Value / Share (Quarterly)$0.35
P/TBV (Annual)4.17x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.89%
Cash Flow / Share (Quarterly)$-0.22
Price vs S&P 500 (YTD)9.58%
Gross Margin (TTM)62.53%
Net Profit Margin (TTM)-21.22%
EPS (TTM)$-0.27
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-0.27
Revenue Growth (5Y)13.78%
EPS (Annual)$-0.27
ROI (Annual)-22.68%
Gross Margin (Annual)62.53%
Net Profit Margin (5Y Avg)-37.82%
Cash / Share (Quarterly)$0.76
Revenue Growth QoQ (YoY)34.75%
ROA (Last FY)-16.77%
Revenue Growth TTM (YoY)9.86%
EBITD / Share (TTM)$-0.14
ROE (5Y Avg)-80.45%
Operating Margin (TTM)-12.20%
Cash Flow / Share (Annual)$-0.22
P/B Ratio11.45x
P/B Ratio (Quarterly)9.88x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.21x
Net Interest Coverage (TTM)-1.42x
ROA (TTM)-18.49%
EV / EBITDA (TTM)245.83x
EPS Incl Extra (Annual)$-0.27
Current Ratio (Annual)5.00x
Quick Ratio (Quarterly)4.15x
3-Month Avg Trading Volume0.12M
52-Week Price Return327.96%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.38
P/S Ratio (Annual)3.15x
Asset Turnover (Annual)0.79x
52-Week High$4.50
Operating Margin (5Y Avg)-34.59%
EPS Excl Extra (Annual)$-0.27
CapEx CAGR (5Y)13.94%
Tangible BV CAGR (5Y)-0.37%
26-Week Price Return34.01%
Quick Ratio (Annual)4.16x
13-Week Price Return5.85%
Total Debt / Equity (Annual)2.40x
Current Ratio (Quarterly)5.00x
Enterprise Value$169.622
Revenue / Share Growth (5Y)9.68%
Asset Turnover (TTM)0.87x
Book Value / Share Growth (5Y)-28.47%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.45x
Pretax Margin (Annual)-20.50%
Cash / Share (Annual)$0.76
3-Month Return Std Dev69.64%
Gross Margin (5Y Avg)64.55%
Net Income / Employee (TTM)$-0
ROE (Last FY)-77.10%
Net Interest Coverage (Annual)-1.42x
EPS Basic Excl Extra (Annual)$-0.27
P/FCF (TTM)47.30x
Receivables Turnover (TTM)3.28x
Total Debt / Equity (Quarterly)2.40x
EPS Incl Extra (TTM)$-0.27
Receivables Turnover (Annual)3.26x
ROI (TTM)-25.44%
P/S Ratio (TTM)3.15x
Pretax Margin (5Y Avg)-38.32%
Revenue / Share (Annual)$1.29
Tangible BV / Share (Annual)$0.62
Price vs S&P 500 (52W)292.86%
Year-to-Date Return13.71%
5-Day Price Return2.58%
EPS Normalized (Annual)$-0.27
ROA (5Y Avg)-28.68%
Net Profit Margin (Annual)-21.22%
Month-to-Date Return7.86%
Cash Flow / Share (TTM)$-0.42
EBITD / Share (Annual)$-0.14
Operating Margin (Annual)-12.20%
LT Debt / Equity (Annual)2.40x
ROI (5Y Avg)-38.45%
LT Debt / Equity (Quarterly)2.40x
EPS Basic Excl Extra (TTM)$-0.27
P/TBV (Quarterly)2.92x
P/B Ratio (Annual)9.88x
Inventory Turnover (TTM)2.45x
Pretax Margin (TTM)-20.50%
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)2.99%
Beta1.56x
P/FCF (Annual)122.41x
Revenue / Share (TTM)$1.25
ROE (TTM)-117.54%
52-Week Low$0.83
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.18
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
APYXApyx Medical Corporation Common Stock | 3.15x | 13.78% | 62.53% | -12.20% | $3.94 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Apyx Medical Corp manufactures energy-based medical devices for cosmetic and surgical markets. Its core products include Renuvion, a controlled heat technology used by plastic and cosmetic surgeons, and J-Plasma, a precision surgical system designed to minimize tissue damage. The company's Advanced Energy segment represents its primary revenue driver.